Not So Different: A Podcast From The Center For Biosimilars

Show notes To read more of Ha Kung's thoughts on the US patent system and its role in the biosimilar landscape, click here. To learn more about Congress' role in addressing AbbVie's alleged anticompetitive practices regarding adalimumab products, click here. To learn more about the suit filed by CareFirst BlueCross BlueShield regarding ustekinumab biosimilar delays, click here. To learn more about the settlements that have resulted in the market delay of ustekinumab biosimilars, click here. To learn more about lawsuits involving AbbVie that led to the delayed market entrance of adalimumab biosimilars, click here. To learn more about what types of patents are at most to blame for biosimilar market delays, click here.